Agilent Technologies (NYSE:A) Stock Price Expected to Rise, Barclays Analyst Says

Agilent Technologies (NYSE:A) had its price target raised by investment analysts at Barclays from $150.00 to $175.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. Barclays‘s target price would indicate a potential upside of 11.31% from the stock’s previous close.

A number of other analysts have also recently commented on the company. Wolfe Research reaffirmed a “hold” rating on shares of Agilent Technologies in a research report on Tuesday, June 2nd. Robert W. Baird boosted their target price on shares of Agilent Technologies from $155.00 to $156.00 and gave the company an “outperform” rating in a research report on Tuesday, May 26th. Royal Bank Of Canada increased their price target on Agilent Technologies from $155.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday. Bank of America upgraded Agilent Technologies from a “neutral” rating to a “buy” rating and reduced their price objective for the company from $150.00 to $145.00 in a research note on Thursday, May 28th. Finally, Piper Sandler assumed coverage on Agilent Technologies in a report on Thursday, June 11th. They issued a “neutral” rating and a $150.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $170.33.

Agilent Technologies Stock Up 1.4%

NYSE A traded up $2.13 on Thursday, reaching $157.22. 1,992,931 shares of the stock traded hands, compared to its average volume of 2,232,849. Agilent Technologies has a 12 month low of $108.35 and a 12 month high of $163.75. The company has a market cap of $44.40 billion, a price-to-earnings ratio of 31.56, a PEG ratio of 2.73 and a beta of 1.25. The company has a fifty day moving average price of $139.16 and a 200-day moving average price of $126.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.62 and a current ratio of 2.10.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.13. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The company had revenue of $1.88 billion for the quarter, compared to analyst estimates of $1.84 billion. During the same quarter in the previous year, the firm earned $1.37 earnings per share. The firm’s quarterly revenue was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. As a group, research analysts forecast that Agilent Technologies will post 6.05 EPS for the current fiscal year.

Hedge Funds Weigh In On Agilent Technologies

Hedge funds and other institutional investors have recently modified their holdings of the business. Greenleaf Trust lifted its position in Agilent Technologies by 0.8% during the 2nd quarter. Greenleaf Trust now owns 8,117 shares of the medical research company’s stock worth $1,078,000 after acquiring an additional 68 shares in the last quarter. Nilsine Partners LLC grew its position in Agilent Technologies by 0.8% in the second quarter. Nilsine Partners LLC now owns 9,650 shares of the medical research company’s stock valued at $1,282,000 after acquiring an additional 72 shares in the last quarter. Fiduciary Trust Co grew its position in Agilent Technologies by 1.6% in the third quarter. Fiduciary Trust Co now owns 4,931 shares of the medical research company’s stock valued at $633,000 after acquiring an additional 77 shares in the last quarter. Sapient Capital LLC raised its stake in shares of Agilent Technologies by 4.2% during the first quarter. Sapient Capital LLC now owns 2,105 shares of the medical research company’s stock valued at $240,000 after purchasing an additional 85 shares during the period. Finally, Plan A Wealth LLC raised its stake in shares of Agilent Technologies by 3.2% during the fourth quarter. Plan A Wealth LLC now owns 2,959 shares of the medical research company’s stock valued at $403,000 after purchasing an additional 92 shares during the period. 87.41% of the stock is owned by hedge funds and other institutional investors.

Key Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 revenue of $1.88 billion, up 8.1% year over year and above the $1.84 billion consensus estimate. Adjusted EPS of $1.62 also exceeded expectations of $1.49, while earnings rose from $1.37 a year earlier. Operating profit and cash flow improved, supporting the view that demand for laboratory, pharmaceutical research, and analytical instruments is recovering. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 outlook to adjusted EPS of $6.18-$6.21, above the $6.06 analyst consensus, and forecast revenue of approximately $7.5 billion versus expectations of $7.4 billion. Fourth-quarter EPS guidance of $1.71-$1.74 was at or above consensus, reinforcing confidence in improving demand and expanding margins. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Several analysts raised their price targets and adopted bullish ratings following the results. JPMorgan lifted its target to $190 and rated the stock “overweight”; RBC raised its target to $185 with an “outperform” rating; and TD Cowen and Bernstein increased targets to $180, with “buy” and “outperform” ratings, respectively. The revisions signal that analysts see additional upside after the earnings beat and guidance increase. Analyst price-target revisions reported by Benzinga

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.